The “Fabry Disease Therapeutic Industry Forecast” looks at past sales and reviews total world Fabry Disease Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Fabry Disease Therapeutic sales for 2023 through 2029. With Fabry Disease Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fabry Disease Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Fabry Disease Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fabry Disease Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Fabry Disease Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fabry Disease Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fabry Disease Therapeutic.
The global Fabry Disease Therapeutic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Fabry Disease Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Fabry Disease Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Fabry Disease Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Fabry Disease Therapeutic players cover Amicus therapeutics, Takeda, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company and GlaxoSmithKline plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Fabry Disease Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Enzyme Replacement Therapy
Alternative therapies
Segmentation by application
Hospitals
Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Fabry Disease Therapeutic Market Size 2018-2029
2.1.2 Fabry Disease Therapeutic Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Fabry Disease Therapeutic Segment by Type
2.2.1 Enzyme Replacement Therapy
2.2.2 Alternative therapies
2.3 Fabry Disease Therapeutic Market Size by Type
2.3.1 Fabry Disease Therapeutic Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Fabry Disease Therapeutic Market Size Market Share by Type (2018-2023)
2.4 Fabry Disease Therapeutic Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Fabry Disease Therapeutic Market Size by Application
2.5.1 Fabry Disease Therapeutic Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Fabry Disease Therapeutic Market Size Market Share by Application (2018-2023)
3 Fabry Disease Therapeutic Market Size by Player
3.1 Fabry Disease Therapeutic Market Size Market Share by Players
3.1.1 Global Fabry Disease Therapeutic Revenue by Players (2018-2023)
3.1.2 Global Fabry Disease Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Fabry Disease Therapeutic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Fabry Disease Therapeutic by Regions
4.1 Fabry Disease Therapeutic Market Size by Regions (2018-2023)
4.2 Americas Fabry Disease Therapeutic Market Size Growth (2018-2023)
4.3 APAC Fabry Disease Therapeutic Market Size Growth (2018-2023)
4.4 Europe Fabry Disease Therapeutic Market Size Growth (2018-2023)
4.5 Middle East & Africa Fabry Disease Therapeutic Market Size Growth (2018-2023)
5 Americas
5.1 Americas Fabry Disease Therapeutic Market Size by Country (2018-2023)
5.2 Americas Fabry Disease Therapeutic Market Size by Type (2018-2023)
5.3 Americas Fabry Disease Therapeutic Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Fabry Disease Therapeutic Market Size by Region (2018-2023)
6.2 APAC Fabry Disease Therapeutic Market Size by Type (2018-2023)
6.3 APAC Fabry Disease Therapeutic Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Fabry Disease Therapeutic by Country (2018-2023)
7.2 Europe Fabry Disease Therapeutic Market Size by Type (2018-2023)
7.3 Europe Fabry Disease Therapeutic Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Fabry Disease Therapeutic by Region (2018-2023)
8.2 Middle East & Africa Fabry Disease Therapeutic Market Size by Type (2018-2023)
8.3 Middle East & Africa Fabry Disease Therapeutic Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Fabry Disease Therapeutic Market Forecast
10.1 Global Fabry Disease Therapeutic Forecast by Regions (2024-2029)
10.1.1 Global Fabry Disease Therapeutic Forecast by Regions (2024-2029)
10.1.2 Americas Fabry Disease Therapeutic Forecast
10.1.3 APAC Fabry Disease Therapeutic Forecast
10.1.4 Europe Fabry Disease Therapeutic Forecast
10.1.5 Middle East & Africa Fabry Disease Therapeutic Forecast
10.2 Americas Fabry Disease Therapeutic Forecast by Country (2024-2029)
10.2.1 United States Fabry Disease Therapeutic Market Forecast
10.2.2 Canada Fabry Disease Therapeutic Market Forecast
10.2.3 Mexico Fabry Disease Therapeutic Market Forecast
10.2.4 Brazil Fabry Disease Therapeutic Market Forecast
10.3 APAC Fabry Disease Therapeutic Forecast by Region (2024-2029)
10.3.1 China Fabry Disease Therapeutic Market Forecast
10.3.2 Japan Fabry Disease Therapeutic Market Forecast
10.3.3 Korea Fabry Disease Therapeutic Market Forecast
10.3.4 Southeast Asia Fabry Disease Therapeutic Market Forecast
10.3.5 India Fabry Disease Therapeutic Market Forecast
10.3.6 Australia Fabry Disease Therapeutic Market Forecast
10.4 Europe Fabry Disease Therapeutic Forecast by Country (2024-2029)
10.4.1 Germany Fabry Disease Therapeutic Market Forecast
10.4.2 France Fabry Disease Therapeutic Market Forecast
10.4.3 UK Fabry Disease Therapeutic Market Forecast
10.4.4 Italy Fabry Disease Therapeutic Market Forecast
10.4.5 Russia Fabry Disease Therapeutic Market Forecast
10.5 Middle East & Africa Fabry Disease Therapeutic Forecast by Region (2024-2029)
10.5.1 Egypt Fabry Disease Therapeutic Market Forecast
10.5.2 South Africa Fabry Disease Therapeutic Market Forecast
10.5.3 Israel Fabry Disease Therapeutic Market Forecast
10.5.4 Turkey Fabry Disease Therapeutic Market Forecast
10.5.5 GCC Countries Fabry Disease Therapeutic Market Forecast
10.6 Global Fabry Disease Therapeutic Forecast by Type (2024-2029)
10.7 Global Fabry Disease Therapeutic Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Amicus therapeutics
11.1.1 Amicus therapeutics Company Information
11.1.2 Amicus therapeutics Fabry Disease Therapeutic Product Offered
11.1.3 Amicus therapeutics Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Amicus therapeutics Main Business Overview
11.1.5 Amicus therapeutics Latest Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Fabry Disease Therapeutic Product Offered
11.2.3 Takeda Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Takeda Main Business Overview
11.2.5 Takeda Latest Developments
11.3 Genzyme-Sanofi
11.3.1 Genzyme-Sanofi Company Information
11.3.2 Genzyme-Sanofi Fabry Disease Therapeutic Product Offered
11.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Genzyme-Sanofi Main Business Overview
11.3.5 Genzyme-Sanofi Latest Developments
11.4 Protalix
11.4.1 Protalix Company Information
11.4.2 Protalix Fabry Disease Therapeutic Product Offered
11.4.3 Protalix Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Protalix Main Business Overview
11.4.5 Protalix Latest Developments
11.5 Sanofi-Aventis LLC
11.5.1 Sanofi-Aventis LLC Company Information
11.5.2 Sanofi-Aventis LLC Fabry Disease Therapeutic Product Offered
11.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sanofi-Aventis LLC Main Business Overview
11.5.5 Sanofi-Aventis LLC Latest Developments
11.6 Novartis Pharmaceuticals
11.6.1 Novartis Pharmaceuticals Company Information
11.6.2 Novartis Pharmaceuticals Fabry Disease Therapeutic Product Offered
11.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Novartis Pharmaceuticals Main Business Overview
11.6.5 Novartis Pharmaceuticals Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Fabry Disease Therapeutic Product Offered
11.7.3 Pfizer Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Information
11.8.2 Bristol-Myers Squibb Company Fabry Disease Therapeutic Product Offered
11.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Bristol-Myers Squibb Company Main Business Overview
11.8.5 Bristol-Myers Squibb Company Latest Developments
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Information
11.9.2 GlaxoSmithKline plc Fabry Disease Therapeutic Product Offered
11.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 GlaxoSmithKline plc Main Business Overview
11.9.5 GlaxoSmithKline plc Latest Developments
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Information
11.10.2 Amgen Inc. Fabry Disease Therapeutic Product Offered
11.10.3 Amgen Inc. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Amgen Inc. Main Business Overview
11.10.5 Amgen Inc. Latest Developments
11.11 Teva pharmaceutical Industries Ltd.
11.11.1 Teva pharmaceutical Industries Ltd. Company Information
11.11.2 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Product Offered
11.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Teva pharmaceutical Industries Ltd. Main Business Overview
11.11.5 Teva pharmaceutical Industries Ltd. Latest Developments
11.12 Merc & Co.
11.12.1 Merc & Co. Company Information
11.12.2 Merc & Co. Fabry Disease Therapeutic Product Offered
11.12.3 Merc & Co. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Merc & Co. Main Business Overview
11.12.5 Merc & Co. Latest Developments
11.13 AbbVie Inc.
11.13.1 AbbVie Inc. Company Information
11.13.2 AbbVie Inc. Fabry Disease Therapeutic Product Offered
11.13.3 AbbVie Inc. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 AbbVie Inc. Main Business Overview
11.13.5 AbbVie Inc. Latest Developments
11.14 Takeda Pharmaceutical Co. Ltd.
11.14.1 Takeda Pharmaceutical Co. Ltd. Company Information
11.14.2 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Product Offered
11.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Takeda Pharmaceutical Co. Ltd. Main Business Overview
11.14.5 Takeda Pharmaceutical Co. Ltd. Latest Developments
11.15 Green Cross Corp.
11.15.1 Green Cross Corp. Company Information
11.15.2 Green Cross Corp. Fabry Disease Therapeutic Product Offered
11.15.3 Green Cross Corp. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Green Cross Corp. Main Business Overview
11.15.5 Green Cross Corp. Latest Developments
12 Research Findings and Conclusion
*If Applicable.